MCID: GRM001
MIFTS: 38

Germ Cell and Embryonal Cancer

Categories: Cancer diseases, Fetal diseases

Aliases & Classifications for Germ Cell and Embryonal Cancer

MalaCards integrated aliases for Germ Cell and Embryonal Cancer:

Name: Germ Cell and Embryonal Cancer 12 14
Neoplasms, Germ Cell and Embryonal 42
Germ Cell and Embryonal Neoplasm 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3095
MeSH 42 D009373
UMLS 69 C0027658

Summaries for Germ Cell and Embryonal Cancer

Disease Ontology : 12 A germ cell cancer that is derives from a mixture of germs cells and embryonal cells.

MalaCards based summary : Germ Cell and Embryonal Cancer, also known as neoplasms, germ cell and embryonal, is related to teratoma and trophoblastic neoplasm. An important gene associated with Germ Cell and Embryonal Cancer is POU5F1 (POU Class 5 Homeobox 1), and among its related pathways/superpathways are Wnt Signaling Pathway and Pluripotency and Mesodermal Commitment Pathway. The drugs Cisplatin and Dacarbazine have been mentioned in the context of this disorder. Affiliated tissues include brain, t cells and lung, and related phenotype is Increased shRNA abundance (Z-score > 2).

Related Diseases for Germ Cell and Embryonal Cancer

Diseases related to Germ Cell and Embryonal Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 53)
id Related Disease Score Top Affiliating Genes
1 teratoma 11.0
2 trophoblastic neoplasm 11.0
3 multiple benign circumferential skin creases on limbs 10.8 KHDC3L NLRP7
4 sertoli cell-only syndrome 10.8 AFP MNX1
5 intracranial hypotension 10.8 AFP POU5F1
6 macular retinal edema 10.7 AFP POU5F1 SOX2
7 gangliosidosis gm1 10.7 AFP MYC
8 malignant syringoma 10.7 AFP ANO6 POU5F1
9 atypical lipomatous tumor 10.7 AFP POU5F1
10 adult endodermal sinus tumor 10.7 AFP LIN28A
11 trisomy 2 mosaicism 10.7 AFP KHDC3L NLRP7
12 mannosidosis, beta 10.7 KLF4 POU5F1 SOX2
13 kidney disease 10.6 AFP TG
14 testicular pure germ cell tumor 10.6 CSH1 CSH2
15 mature teratoma 10.6 AFP ANO6 TG
16 microcephaly, seizures, and developmental delay 10.6 CDKN1C KHDC3L NLRP7
17 post-surgical hypoinsulinemia 10.6 MYC POU5F1 SOX2
18 autosomal dominant sideroblastic anemia 10.5 AFP CDKN1C MNX1
19 intestine carcinoma in situ 10.5 AFP FUT4
20 gingival hypertrophy 10.5 AFP CSH1 CSH2
21 uveal melanoma 10.5 AFP CSH1 CSH2
22 inner ear cancer 10.5 AFP FUT4
23 articulation disorder 10.5 AFP CSH1 CSH2
24 testicular malignant germ cell cancer 10.4 CSH1 CSH2
25 breast disease 10.4 AFP CSH1 CSH2
26 eccrine acrospiroma 10.4 AFP KRT7
27 ovarian cystic teratoma 10.4 AFP FUT4 POU5F1
28 visual cortex disease 10.4 AFP NANOG POU5F1 SOX2
29 neurodermatitis 10.4 AFP FUT4 POU5F1
30 anterolateral myocardial infarction 10.4 AFP NANOG POU5F1 SOX2
31 central nervous system sarcoma 10.4 AFP FUT4 POU5F1
32 ampulla of vater adenocarcinoma 10.3 KRT7 MYC
33 clear cell squamous cell skin carcinoma 10.3 AFP KRT7
34 demyelinating polyneuropathy 10.3 AFP TG
35 mucinous cystadenocarcinoma 10.2 CDKN1C CSH1 CSH2
36 testicular trophoblastic tumor 10.2 AFP KRT7
37 mediastinum synovial sarcoma 10.2 AFP KRT7 TG
38 agnosia 10.1 CDKN1C CSH1 KHDC3L NLRP7 PAM
39 malignant sertoli-leydig cell tumor 10.1 KRT7 POU5F1
40 uremia 10.1 KLF4 MYC NANOG POU5F1 SOX2
41 skin tag 10.1 AFP CDKN1C KRT7
42 gallbladder cancer 10.1 AFP KRT7 MYC
43 breast secretory carcinoma 10.1 AFP KRT7
44 cerebellar vermis medulloblastoma 10.1 AFP KRT7
45 epidermolytic acanthoma 9.9 CSH1 CSH2
46 central nervous system disease 9.9 AFP KRT7 MNX1 POU5F1 SOX2
47 microcystic meningioma 9.9 FUT4 KLF4 KRT7
48 testicular germ cell cancer 9.9 AFP CSH1 CSH2 KRT7
49 vulvar angiokeratoma 9.9 FUT4 KRT7
50 brown-vialetto-van laere syndrome 9.8 AFP KRT7 MYC POU5F1 SOX2

Graphical network of the top 20 diseases related to Germ Cell and Embryonal Cancer:



Diseases related to Germ Cell and Embryonal Cancer

Symptoms & Phenotypes for Germ Cell and Embryonal Cancer

GenomeRNAi Phenotypes related to Germ Cell and Embryonal Cancer according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-114 9.47 AFP
2 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.47 AFP
3 Increased shRNA abundance (Z-score > 2) GR00366-A-123 9.47 POU5F1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-127 9.47 POU5F1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-135 9.47 KRT7
6 Increased shRNA abundance (Z-score > 2) GR00366-A-149 9.47 POU5F1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-192 9.47 POU5F1 AFP KRT7
8 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.47 AFP
9 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.47 POU5F1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.47 AFP
11 Increased shRNA abundance (Z-score > 2) GR00366-A-74 9.47 KRT7 POU5F1

Drugs & Therapeutics for Germ Cell and Embryonal Cancer

Drugs for Germ Cell and Embryonal Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 858)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
2
Dacarbazine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 4342-03-4 5351166
3
Vindesine Approved Phase 4,Phase 3,Phase 2 59917-39-4, 53643-48-4 40839
4
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2 50-23-7 5754 657311
5
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2 53-03-2 5865
6
Somatostatin Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 38916-34-6, 51110-01-1 53481605
7
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 41575-94-4 10339178 498142 38904
8
Everolimus Approved Phase 4,Phase 3,Phase 1,Phase 2 159351-69-6 6442177
9
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
10
Paclitaxel Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 33069-62-4 36314
11
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 53123-88-9 5284616 6436030 46835353
12
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 33419-42-0 36462
13
Ifosfamide Approved Phase 4,Phase 3,Phase 2,Phase 1 3778-73-2 3690
14
Mechlorethamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-75-2 4033
15
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
16
Lenograstim Approved Phase 4,Phase 2,Phase 3,Phase 1 135968-09-1
17
Mesna Approved Phase 4,Phase 3,Phase 1,Phase 2 3375-50-6 598
18
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
19 Thiotepa Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 52-24-4 5453
20
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
21
Octreotide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 83150-76-9 383414 6400441
22
Temozolomide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 85622-93-1 5394
23
Sunitinib Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 341031-54-7, 557795-19-4 5329102
24
Dasatinib Approved, Investigational Phase 4,Phase 2,Phase 1 302962-49-8 3062316
25
Sorafenib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 284461-73-0 216239 406563
26
Trametinib Approved Phase 4,Phase 3,Phase 2,Phase 1 871700-17-3 11707110
27
Aldesleukin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 85898-30-2, 110942-02-4
28 lanreotide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 108736-35-2
29
Itraconazole Approved, Investigational Phase 4,Phase 1 84625-61-6 55283
30
Etanercept Approved, Investigational Phase 4,Phase 2 185243-69-0
31
Pancrelipase Approved Phase 4,Phase 2,Phase 1 53608-75-6
32
Triamcinolone Approved, Vet_approved Phase 4,Phase 2 124-94-7 31307
33
Nicotine Approved Phase 4 54-11-5 942 89594
34
Bortezomib Approved, Investigational Phase 4,Phase 2,Phase 1 179324-69-7 387447 93860
35
Gefitinib Approved, Investigational Phase 4,Phase 1,Phase 2 184475-35-2 123631
36
Ramucirumab Approved, Investigational Phase 4,Phase 2,Phase 1 947687-13-0
37
Vorinostat Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 149647-78-9 5311
38
Benzocaine Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 1994-09-7, 94-09-7 2337
39
Ceritinib Approved Phase 4,Phase 2,Phase 1,Early Phase 1 1032900-25-6
40
Crizotinib Approved Phase 4,Phase 3,Phase 2,Phase 1 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
41
Olaparib Approved Phase 4,Phase 2,Phase 1 763113-22-0 23725625
42
Palbociclib Approved Phase 4,Phase 2,Phase 1 571190-30-2 11431660 5005498 5330286
43
Zinc Approved Phase 4,Phase 1 7440-66-6 32051 23994
44
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 59-30-3 6037
45
leucovorin Approved, Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1 58-05-9 143 6006
46 tannic acid Approved, Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
47 Pancreatic Polypeptide Investigational Phase 4,Phase 2,Phase 3,Phase 1 59763-91-6
48 Etiracetam Investigational Phase 4,Phase 2 33996-58-6
49
Butyric Acid Experimental Phase 4,Phase 2 107-92-6 264
50
Lactitol Investigational Phase 4,Phase 1,Phase 2 585-86-4 3871

Interventional clinical trials:

(show top 50) (show all 4083)

id Name Status NCT ID Phase Drugs
1 Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors Unknown status NCT00454376 Phase 4
2 Conformation of Beta Human Chorionic Gonadotropin During Chemotherapy for Choriocarcinoma Unknown status NCT00294177 Phase 4
3 Correlation Between SV2A Expression in Tumour Tissue and Efficacy of Levetiracetam in Glioma Patients With Epilepsy Unknown status NCT00454935 Phase 4
4 Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy in Metastasized Malignant Melanoma Unknown status NCT00226473 Phase 4 Cisplatin, Vindesine, Dacarbazine (drugs)
5 Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar Lesions Unknown status NCT02190994 Phase 4 Hydrocortisone;Prednisone
6 Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients Completed NCT02075606 Phase 4 lanreotide acetate
7 RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation Completed NCT01317615 Phase 4 RAD001;Paclitaxel;Carboplatin
8 Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced Neuroendocrine Tumors Completed NCT01595009 Phase 4 RAD001
9 Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation Completed NCT00336531 Phase 4 itraconazole
10 Somatuline Autogel Preference and Health Economy Study Completed NCT00681187 Phase 4 lanreotide (Autogel formulation)
11 Can We Miss Pigmented Lesions in Psoriasis Patients? Completed NCT01053819 Phase 4 etanercept
12 Randomized Clinical Trial of Posterior Retroperitoneoscopic Adrenalectomy Versus Lateral Laparoscopic Adrenalectomy Completed NCT01959711 Phase 4
13 Prospective Trial for the Diagnosis and Treatment of Intracranial Germ Cell Tumors Recruiting NCT01424839 Phase 4 Carboplatin, Etoposide, Ifosfamide;Cisplatin, etoposide, Ifosfamide (standard);Cisplatin, Etoposide, Ifosfamide (high dose)
14 HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors Recruiting NCT02875314 Phase 4 Induction;Single Cycle Intensive Chemotherapy;Tandem 3 Cycle Intensive Chemotherapy
15 Radiolabeled Molecules for Medullary Thyroid Cancer Recruiting NCT01915485 Phase 4
16 A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer Recruiting NCT01896479 Phase 4 Cabozantinib (XL184) 140 mg;Cabozantinib (XL184) 60 mg;Placebo tablet;Placebo capsule
17 A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide Recruiting NCT03289741 Phase 4 Octreotide;LAR Lanreotide
18 Nonfunctional Pancreatic NET and PET Imaging Recruiting NCT02621541 Phase 4
19 Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China Recruiting NCT02842749 Phase 4 everolimus
20 Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study. Recruiting NCT01794793 Phase 4 Pasireotide
21 Supra-early Post-Surgery Chemotherapy in the Treatment on GBM Patients Recruiting NCT02520635 Phase 4 supra-early TEMODAL® chemotherapy;standard TEMODAL® chemotherapy
22 Clinical Effectiveness of Serum Chromogranin A Levels on Diagnostic of Pancreatic Neuroendocrine Tumors Active, not recruiting NCT02759718 Phase 4
23 Stereotactic Body Radiotherapy for Head and Neck Tumors Active, not recruiting NCT01344356 Phase 4
24 A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors Active, not recruiting NCT01525550 Phase 4 sunitinib
25 TTT Versus TTT and Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy Active, not recruiting NCT02379000 Phase 4 Triamcinolone Acetonide
26 Study of Lanreotide in Metastatic or Recurrent Grade I-II Hindgut NET Active, not recruiting NCT03083210 Phase 4 Lanreotide
27 An Open-Label Study of Zelboraf (Vemurafenib) in Patients With Braf V600 Mutation Positive Metastatic Melanoma Active, not recruiting NCT01898585 Phase 4 Zelboraf
28 A National Phase IV Study With Ipilimumab for Patients With Advanced Malignant Melanoma. Active, not recruiting NCT02068196 Phase 4 Ipilimumab
29 G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor Not yet recruiting NCT02933333 Phase 4
30 Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma Not yet recruiting NCT02645149 Phase 4 Standard therapy or clinical trial;Matched targeted therapy;Trametinib and / or supportive care
31 Assessment of Optune Therapy for Patients With Newly Diagnosed Glioblastoma Using Advanced MRI Not yet recruiting NCT03297125 Phase 4
32 HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma Terminated NCT01856023 Phase 4 High Dose Interleukin-2;Ipilimumab
33 HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma Terminated NCT01683188 Phase 4 vemurafenib + HD IL-2
34 Post-approval Study of NovoTTF-100A in Recurrent GBM Patients Terminated NCT01756729 Phase 4
35 Pasireotide Treatment for Neuroendocrine Tumor Withdrawn NCT02779257 Phase 4 Pasireotide;Diazoxide
36 Observation and/or Combination Chemotherapy After Surgery or Biopsy in Treating Young Patients With Extracranial Germ Cell Tumors Unknown status NCT00274950 Phase 3 carboplatin;cisplatin;etoposide;ifosfamide;vinblastine sulfate
37 Combination Chemotherapy in Treating Men With Germ Cell Cancer Unknown status NCT00003643 Phase 2, Phase 3 cisplatin;etoposide;paclitaxel
38 Combination Chemotherapy With Bone Marrow Transplantation in Treating Men With Germ Cell Tumors Unknown status NCT00002566 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;ifosfamide;vinblastine sulfate
39 Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors Unknown status NCT00104676 Phase 3 cisplatin;etoposide;ifosfamide;oxaliplatin;paclitaxel
40 Magnetic Resonance Imaging and Computed Tomography in Patients With Stage I Seminoma of the Testicle Unknown status NCT00589537 Phase 3
41 Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer Unknown status NCT01087268 Phase 3
42 Stem Cell Transplant for High Risk Central Nervous System (CNS) Tumors Unknown status NCT00179803 Phase 2, Phase 3
43 Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer Unknown status NCT00704730 Phase 3 XL184;Placebo
44 Lerisetron Compared With Granisetron in Preventing Nausea and Vomiting in Men Being Treated With Radiation Therapy for Stage I Seminoma Unknown status NCT00004219 Phase 3 granisetron hydrochloride;lerisetron
45 Study to Investigate the Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut Unknown status NCT00171873 Phase 3 Octreotide LAR (Long-acting release);Placebo
46 Immunotherapy After Surgery in Treating Patients With Breast Cancer, Colon Cancer, or Melanoma Unknown status NCT00002455 Phase 3
47 Quality of Life in Patients Who Have Undergone Previous Treatment for Primitive Neuroectodermal Tumors Unknown status NCT00278239 Phase 3
48 Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors Unknown status NCT00227617 Phase 2, Phase 3 5-fluorouracil;leucovorin;oxaliplatin
49 Therapy Optimization Trial for the Treatment of Relapsed or Refractory Brain Tumors in Children Unknown status NCT00749723 Phase 2, Phase 3 carboplatin;etoposide;temozolomide;thiotepa, carboplatin, etoposide;temozolomide, thiotepa;etoposide;trofosfamide/etoposide
50 Efficacy of Tranexamic Acid in Brain Tumor Resections Unknown status NCT01655927 Phase 3 Tranexamic Acid;Placebo: Saline

Search NIH Clinical Center for Germ Cell and Embryonal Cancer

Cochrane evidence based reviews: neoplasms, germ cell and embryonal

Genetic Tests for Germ Cell and Embryonal Cancer

Anatomical Context for Germ Cell and Embryonal Cancer

MalaCards organs/tissues related to Germ Cell and Embryonal Cancer:

39
Brain, T Cells, Lung, Thyroid, Liver, Bone, Kidney

Publications for Germ Cell and Embryonal Cancer

Variations for Germ Cell and Embryonal Cancer

Expression for Germ Cell and Embryonal Cancer

Search GEO for disease gene expression data for Germ Cell and Embryonal Cancer.

Pathways for Germ Cell and Embryonal Cancer

GO Terms for Germ Cell and Embryonal Cancer

Biological processes related to Germ Cell and Embryonal Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 transcription from RNA polymerase II promoter GO:0006366 9.71 KLF4 MYC POU5F1 SOX2
2 regulation of gene expression GO:0010468 9.56 MYC NANOG POU5F1 SOX2
3 response to growth factor GO:0070848 9.37 MYC SOX2
4 stem cell population maintenance GO:0019827 9.33 KLF4 LIN28A NANOG
5 hormone biosynthetic process GO:0042446 9.32 DIO3 TG
6 endodermal cell fate specification GO:0001714 9.13 NANOG POU5F1 SOX2
7 somatic stem cell population maintenance GO:0035019 9.02 KLF4 LIN28A NANOG POU5F1 SOX2

Molecular functions related to Germ Cell and Embryonal Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 transcription factor activity, sequence-specific DNA binding GO:0003700 9.73 KLF4 MNX1 MYC NANOG POU5F1 SOX2
2 sequence-specific DNA binding GO:0043565 9.55 KLF4 MNX1 NANOG POU5F1 SOX2
3 hormone activity GO:0005179 9.13 CSH1 CSH2 TG
4 miRNA binding GO:0035198 8.8 LIN28A POU5F1 SOX2

Sources for Germ Cell and Embryonal Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....